N-aryl pyrrolidine derivatives as beta-secretase inhibitors

Details N-aryl pyrrolidine derivatives as beta-secretase inhibitors N-aryl pyrrolidine derivatives as beta-secretase inhibitors

2007-03-29

2008-08-05

Anderson, Rebecca L (Department: 4131)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S577000, C548S400000, C514S359000, C514S408000, C514S429000

Reexamination Certificate

active

07408071

ABSTRACT:
There is provided a series of substituted N-aryl pyrrolidine derivatives of Formula (I)or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R5′, R6, R7, and p as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

REFERENCES:
patent: WO 99/033460 (1998-12-01), None
Hussain, I. et al., “Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase”,Mol. Cell. Neurosci, (1999) 14: 419-427.
Lin, X. et al., “Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein”, Proceedings of the National Academy of Sciences of the USA, (2000) 97:1456-1460.
Luo, Y., et al., “Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation”,Nature Neuroscience(2001) 4: 231-232.
Roberds, S.L. et al., “BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics”,Human Molecular Genetics(2001) 10: 1317-1324.
Seiffert, D.; et al., “Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors”,J. Biol. Chem.(2000) 275, 34086-34091.
Selkoe, D. J., “Alzheimer's Disease: Genes, Proteins, and Therapy”,Physiol. Rev.(2001) 81, 741-766.
Selkoe, D. J., “Biochemical Analyses of Alzheimer's Brain Lesions lead to the Identification of αβ and its Precursor”,Ann. Rev. Cell Biol.(1994) 10: 373-403.
Sinha, S., et al., “Purification and cloning of amyloid precursor protein β-secretase from human brain”,Nature(London) (1999) 402: 537-540.
Thal, D. R., et al., “Two types of Sporadic Cerebral Amyloid Angiopathy”,J. Neuropath. and Exper. Neurology(2002) 61: 282-293.
Vassar, R., et al., “β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE”,Science(1999) 286: 735-741.
Walsh, D. M., et al., “Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo”,Nature(2002) 416, 535-539.
Wolfe, M. S., “Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential”,J. Med. Chem.(2001) 44, 2039-2060.
Yan, R. et al., “Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity”,Nature(1999) 402: 533-537.

Affiliated with

Also associated with

Rating

N-aryl pyrrolidine derivatives as beta-secretase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N-aryl pyrrolidine derivatives as beta-secretase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-aryl pyrrolidine derivatives as beta-secretase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4009485